share_log

PreveCeutical Announces Change of Auditors

PreveCeutical Announces Change of Auditors

PreveCeutical宣佈更換核數師
newsfile ·  2024/12/19 05:30

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that the Company has changed its auditor from Smythe LLP, Certified Public Accountants ("Former Auditor") to Davidson & Company LLP, Certified Professional Accounts ("Successor Auditor") effective December 18, 2024.

不列顛哥倫比亞省溫哥華--(資訊 CORP - 2024年12月18日) - PreveCeutical 醫療公司 (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("公司"或"PreveCeutical"), 宣佈公司已將核數師由 Smythe LLP 註冊會計師 ("前核數師") 更換爲 Davidson & Company LLP 註冊專業會計師 ("繼任核數師"), 自2024年12月18日起生效。

PreveCeutical's board of directors accepted the resignation of the Former Auditor and appointed the Successor Auditor as the new auditor of the Company effective December 18, 2024, and to hold office until the close of the Company's next annual general meeting of shareholders.

PreveCeutical 的董事會接受了前核數師的辭職,並於2024年12月18日起聘請繼任核數師爲公司的新核數師,並在公司下一次股東年度大會結束之前擔任職務。

There were no reservations in the Former Auditor's audit reports for any financial period during which the Former Auditor was the Company's auditor. There are no "reportable events" (as the term is defined in National Instrument 51-102 - Continuous Disclosure Obligations) between the Company and the Former Auditor.

在前核數師擔任公司核數師期間,沒有任何財務期間的審計報告存在保留意見。公司與前核數師之間沒有 "報告事項" (此術語在國家工具51-102 - 持續披露義務中定義)。

In accordance with National Instrument 51-102, the Notice of Change of Auditor, together with the required letters from the Former Auditor and the Successor Auditor, have been reviewed by the Company's audit committee and board of directors and will be filed on SEDAR accordingly.

根據國家工具51-102,核數師更換通知以及前核數師和繼任核數師的相關信件已由公司的審計委員會和董事會審查,並將相應提交至 SEDAR。

About PreveCeutical

關於PreveCeutical

PreveCeutical is a health sciences company focused on developing innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.

PreveCeutical 是一家醫學科學公司,專注於開發使用有機和自然相同產品的創新預防和治癒療法。公司旨在成爲預防醫學科學板塊的領導者。

With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.

在完成三項研究項目後,公司的產品開發、臨床試驗和商業化工作正在積極進行,並已提交多項臨時專利申請以保護其研究項目的知識產權。

For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook.

欲了解更多關於 PreveCeutical 的信息,請訪問我們的官方網站或在 Twitter 和 Facebook 上關注我們。

On behalf of the Board of Directors of PreveCeutical

代表PreveCeutical的董事會

Stephen Van Deventer, Chairman, Chief Executive Officer and interim Chief Financial Officer

Stephen Van Deventer,董事長,首席執行官及臨時首席財務官

For further information, please contact:

如需更多信息,請聯繫:

Stephen Van Deventer: +1 604 306 9669

Stephen Van Deventer: +1 604 306 9669

Or Investor Relations ir@preveceutical.com

或投資者關係 ir@preveceutical.com

Forward-Looking Statements

前瞻性聲明

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's plans relating to the development, clinical trials and commercialization of its products; and management expectations that it will miss the filing deadline for the Annual Filings and the Company's ability to file the Annual Filings within the time period described herein.

關於前瞻性陳述的注意事項:本發佈包含某些可能構成依據適用的加拿大證券法的前瞻性信息的陳述和信息。前瞻性陳述涉及未來事件或未來表現,反映了公司管理層對未來事件的預期或信念。通常,前瞻性陳述和信息可通過使用前瞻性術語如「打算」或「預期」,或這些詞和短語的變體,或某些行爲、事件或結果「可能」、「可以」、「應該」、「將」或「發生」等陳述來識別。此信息和這些陳述在此稱爲「前瞻性陳述」,並非歷史事實,基於本新聞發佈之日期作出,包括但不限於,關於未來計劃、估計和預測的討論聲明,以及管理層對其預期和意圖的聲明,涉及公司與其產品的開發、臨床試驗及商業化相關的計劃;以及管理層預期未能在上述時間範圍內提交年度資料的能力。

These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the Company being unable to execute its business plans as intended; the Company being unable to file the Annual Filings in the proposed timeframe; recent market volatility; and the state of the financial markets for the Company's securities.

這些前瞻性陳述涉及衆多風險和不確定性,實際結果可能與任何前瞻性陳述所暗示的結果有重大差異。這些風險和不確定性包括但不限於:公司無法如預期執行其業務計劃;公司無法在提議的時間框架內提交年度資料;近期市場波動;以及公司證券的金融市場狀況。

In making the forward-looking statements in this news release, the Company has applied certain material assumptions, including without limitation, that: the Company will be able to execute its business plans as intended; the Company will be able to file the Annual Filings in the proposed time frame.

在本新聞稿中做出的前瞻性聲明中, 公司已應用某些重要假設,包括但不限於: 公司將能夠按照預期執行其業務計劃; 公司將能夠在提議的時間框架內提交年度備案。

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

儘管公司管理層已試圖識別可能導致實際結果與前瞻性聲明或前瞻性信息中所含結果有重要差異的重要因素,但可能還有其他因素導致結果未能如預期、估算或意圖那樣。無法保證這些聲明將被證明是準確的,實際結果和未來事件可能與此類聲明中所預期的有重要差異。因此,讀者不應對前瞻性聲明和前瞻性信息置於過度信任。讀者需謹慎,信賴此類信息可能不適合其他目的。公司不承擔更新在此引用的任何前瞻性聲明、前瞻性信息或財務展望的義務,除非根據適用的證券法規定。我們尋求安全港。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論